Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2005

View Archived Issues

MOR-102 study in animal model of psoriasis is inconclusive

Single-shot vaccine protects monkeys against Ebola challenge

Preclinical efficacy of VEGFR2 vaccine in atherosclerosis

A novel mechanism for aspirin as a preventative therapy for atherosclerosis

In vivo evidence of hypolipidemic and antiatherosclerotic effects for TAK-475

Sunesis obtains rights to anticancer compound from BMS

Migenix receives Canadian clearance for phase I/II study of MX-4509

Isotechnika gets go-ahead for phase IIb kidney transplant study of ISA-247

GlaxoSmithKline to acquire Corixa

Serono to develop Genmab's HuMax-TAC

Completion of phase I study of VRX-496 HIV gene therapy

NDA submission for Emezine

Ariad's IND for oral AP-23573 now effective

Life Medical Sciences now known as SyntheMed

Receptor Biologix raises Series A financing to advance Dimercept

Prous Science to host 3rd Annual U.S. Forum

SCH-391 reduces serum testosterone and tumor volume in mouse xenograft model

WAY-181484: Orally available microtubule-binding agent with antitumor activity in vivo

105AD7 vaccine demonstrates activity in osteosarcoma patients

New intravenous formulation of paclitaxel can be rapidly administered

Ranibizumab and verteporfin PDT tested in choroidal neovascularization model

Pharmacokinetics and pharmacodynamics of CHF-3381 studied in healthy volunteers

Oral-lyn insulin spray approved in Ecuador

Novartis files oral iron chelator Exjade in U.S., Europe

Recent patents cover new treatments for metabolic disorders

Update on the safety and immunogenicity of recombinant MVA-BN-based vaccines

New preclinical data on the anticancer efficacy of beta-elemene

New patents cover therapeutic agents for cardiovascular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...